BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024. In the quarter to June 2026, revenue grew 64.4%, EPS grew 817.3%, free cash flow grew 400.7% and total debt rose 74.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow BLLN
BillionToOne, Inc. (BLLN) P/E ratio
As of 16 October 2026, BillionToOne, Inc. (BLLN) trades at a P/E ratio of 95.0×. Over the past ten years it has ranged from 0.0× (December 2025) to 1,599× (January 2026); the current reading is higher than 30% of that period. That is above the Diagnostics & Research industry median of 35.6× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1,320× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 116× | 23.47% |
| Mar 2026 | 94.1× | (92.87%) |
| Dec 2025 | 1,320× | — |
| Sep 2025 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| RDNT RadNet, Inc. compare | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| QGEN QIAGEN N.V. compare | 23.6× |
| CDNA CareDx, Inc. compare | 29.7× |
| VCYT Veracyte, Inc. compare | 29.9× |
| SHC Sotera Health Company compare | 31.4× |
| BLLN BillionToOne, Inc. | 95.0× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)